About the Journal


Aims and Scope

Biotarget (ISSN 2522-669X; biotarget.amegroups.com; biotarget.amegroups.org) is a peer-reviewed journal devoted to the rapid publication of high quality studies related to identifying key biotarget molecules and the application of biotarget molecules in human and animal diseases. The principal aim of Biotarget is to provide an insight for researchers to develop molecular tools and identify molecular targets for the diagnosis and treatment of a variety of diseases (including cancer, diabetes, neurodegeneration, heart disease, inflammation, immune disease and metabolic disease etc.).

The journal publishes original articles, short communications, reviews, case report and editorials, etc. The journal welcomes research on all aspects of molecular biology and molecular medicine, ranging from biochemistry to molecular physiology, molecular pathology, molecular genetics, molecular diagnostics, and molecular therapy. All material submitted to this journal undergo appropriate review via referees who are experts in this field. All materials submitted follow international guideline with regards to approval of experiments on humans and animals.

Information for Authors

Biotarget is a member of Committee on Publication Ethics (COPE) and it follows the Committee on Publication Ethics (COPE)'s guidelines and the ICMJE recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journal.

Manuscripts submitted must be the original work of the author(s) and must not be published previously or under consideration for publication elsewhere.

Submission Turnaround Time

  • Submission to First Editorial Decision: 1-3 weeks.
  • External peer review: 1-3 months.
  • Acceptance to Publication: 1-4 weeks. Original Articles are listed as priority.

Open Access Statement

Biotarget is a peer reviewed, open access journal. All content of the journal is published under the Creative Commons Attribution-NonCommercial- NoDerivatives 4.0 International License (CC BY-NC-ND 4.0). All articles published open access will be immediately and permanently free for all to read, download, copy and distribute as defined by the applied license.

Free access and usage
Permitted third party reuse is defined by the CC BY-NC-ND 4.0 license. This license allows users to copy and distribute the article, provided:

  • this is not done for commercial purposes and further does not permit distribution of the Article if it is changed or edited in any way.
  • the user gives appropriate credit (with a link to the formal publication through the relevant DOI) and provides a link to the license but not in an any way implying that the licensor is endorsing the user or the use of the work.
  • no derivatives including remix, transform, or build upon the material was allowed for distribution.
The full details of the license are available at https://creativecommons.org/licenses/by-nc-nd/4.0/


For open access publishing, this journal uses an exclusive licensing agreement. Authors will transfer copyright to Biotarget, but will have the right to share their article in the same way permitted to third parties under the relevant user license, as well as certain scholarly usage rights.

For any inquiry/special circumstance on the copyright, commercial usage or adaptation of Biotarget articles, please contact: permissions@amegroups.com

For reprint order, please contact: sales@amegroups.com

Editorial Office

Email: biotarget@amegroups.com

Publisher Information

Biotarget is published by AME Publishing Company.
Address: Flat/RM C 16F, Kings Wing Plaza 1, NO. 3 on Kwan Street, Shatin, NT, Hong Kong, China.

Updated on July 07, 2023